0.04
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Noxopharm
Its shares trade on ASX under the ticker NOX.AX. It has been listed since 9 August 2016. In the fiscal year to 30 June 2026, it reported revenue of A$1.4m and a net loss of A$4.5m. At that date it held total assets of A$1.8m and shareholders' equity of −A$3.6m.
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Castle Hill, New South Wales. The company went IPO on 2016-08-09. The firm is engaged in the discovery and development of treatments for cancer and inflammation. The firm has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. The company is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Aug 2016
- Employees
- 1,000
- Website
- noxopharm.com ↗
Leadership
Pay as last reported
- Mr. Frederick BartNon-Executive Chairman of the Board£45,000
- Ms. Gisela MautnerChief Executive Officer, Executive Managing Director, Director, since 2022£833,980
- Mr. Peter MarksNon-Executive Deputy Chairman of the Board£60,000
- Mr. Shawn Van BoheemenChief Financial Officer
- Ms. Jeanette BellChief Operating Officer
- Mr. David FranksCompany Secretary£16,490
- Mr. Boris PatkinNon-Executive Director£103,669
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Noxopharm Ltd employs 1,000 full-time staff members in Castle Hill.
- The firm has three active drug development programs for cancer treatment.
- Veyonda serves as an adjuvant therapy for late-stage cancers.
Weaknesses
- The company went public on 9 August 2016 with limited history.
- Castle Hill is a small city for a large biotech firm.
- Only one clinical drug candidate is currently active in trials.
Opportunities
- The Chroma platform explores bioactive properties in the anti-cancer space.
- The Sofra platform targets inflammation using short nucleic acid sequences.
- NOX66 is being studied for treating COVID-19 infection.
Threats
- Cancer treatment requires extensive and costly clinical trial phases.
- Inflammation therapies face competition from established pharmaceutical companies.
- COVID-19 research outcomes may not yield viable commercial drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.